Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — Investor Presentation (January 2026)
28 slides from Cg Oncology's investor presentation, Jan 9, 2026
Slide 1: Attacking Bladder Cancer for a Better Tomorrow
Attacking Bladder Cancer for a Better Tomorrow™
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and
Slide 3: The Promise of Cretostimogene
The Promise of Cretostimogene BOND-003 Cohort C (HR BCG UR CIS only)1: 76% CR anytime 46.4% (12-mo) 41.8% (24-mo) BOND-003 Cohort P (HR BCG UR Ta/T1 Disease)2 95.7% (3-mo) HG-EFS 84.6% (6-mo) 80.4% (9-mo) CORE-008 Cohort A (HR BCG Naïve CIS)2 88% CR anytime Potential Best-in-Disease Durability and E
Slide 4: Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC
Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC Addressing a Multi-Billion Dollar Market Opportunity COMPOUND/INDICATION PHASE 1 PHASE 2 PHASE 3 MILESTONES Cretostimogene Monotherapy High-Risk BCG-Unresponsive NMIBC (BOND-003 Cohort C)1 Cretostimogene Monotherapy Intermediate-Risk NM
Slide 5: Cretostimogene's Dual Mechanism of Action
Cretostimogene’s Dual Mechanism of Action: Selective Tumor Killing Triggers Durable Anti-Tumor Immune Response Progeny viruses are released and enter new cancer cells Cretostimogene stimulates cytokine and antigen release 1a 1b Attacking Bladder Cancer for a Better Tomorrow™ Cancer Cell Creto Progen
Slide 6: NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer
Bladder wall Lamina Propria Inner Muscle Deep Muscle Inside of the bladder wall Outside of the bladder wall Carcinoma in Situ (CIS) Non-Invasive Papillary Carcinoma Tumor Invades Connective Tissue Tumor Invades Deep Muscle Tumor Invades Perivesical Tissue Tumor Invades Adjacent Tissue and Organs Tum
Slide 7: Patient Journey
Patient Journey 2 Testing Work-up may include cystoscopy, urine cytology, and imaging (CT scan, MRI) 1 Symptoms Patient presents to primary care and/or urologist with symptoms (hematuria, urinary frequency) 3 TURBT1 TURBT, followed by tumor staging and grading Ongoing Treatment Require surveillance
Slide 8: Cretostimogene is Intravesically Administered Similar to BCG
GAG Layer Tumor Standard Catheter Cretostimogene Cretostimogene is Intravesically Administered into the Bladder, Similar to Standard-of-Care BCG Therapy Which Urology Practices Perform Regularly BCG = Bacillus Calmette Guerin. DDM = n-Dodecyl β-D-maltoside. GAG = glycosaminoglycan. Procedure Can Be
Slide 9: Programs Address More Than 70% of NMIBC Market Potential
NMIBC (75%) Intermediate-Risk (30%) High-Risk (40%) BCG-Exposed BCG-Unresponsive BOND-003 Ph 3 Monotherapy Cohort C and Cohort P Cretostimogene Programs Across High-Risk & Intermediate-Risk NMIBC Address More Than 70% of NMIBC Market Potential Note: CORE-001, CORE-008 Cohort B, and PIVOT-006 are in
Slide 10: Cretostimogene Monotherapy for HR BCG-Unresponsive NMIBC (BOND-003)
Phase 3 Cretostimogene Monotherapy for High-Risk (HR) BCG-Unresponsive NMIBC (NCT04452591) Cohort C DoR CR at 12 months PFS Cohort P RFS PFS Additional Endpoints HR BCG-Unresponsive NMIBC Cretostimogene Single-Arm, Open-Label, Intravesical Administration CR at Any Time (CIS) EFS (Ta/T1) Study Design
Slide 11: BOND-003 Cohort C Overall Complete Response
BOND-003 Cohort C Overall Complete Response 75.5% (95% CI, 66.3% - 83.2%) CR (n=83) 25 Overall CR Rate (%) (n=110) 50 75 100 0 Efficacy data cutoff as of June 23, 2025. Efficacy analysis are centrally confirmed. All patients have active disease at baseline prior to enrollment. Received adequate BCG
Slide 12: Best-in-Disease Complete Response Rate at 24 Months
Cretostimogene Has Delivered Best-in-Disease Complete Response (CR) Rate at 24 Months Cretostimogene demonstrated best-in-disease long-term DoR compared to approved drugs1 in NMIBC with 41.8% of patients in CR at 24 months 90% of patients in CR at 12 months maintained in CR at 24 months No grade 3+
Slide 13: Notes and References for Comparative Data
1 These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies. From published data. 2 All 9 ongoing CRs remained in response at the 24-month assessment, as well
Slide 14: Promising Early HG-EFS in Papillary-Only BCG-Unresponsive NMIBC
Cretostimogene Demonstrates Promising Early HG-EFS in High-Risk, Papillary-Only BCG-Unresponsive NMIBC BOND-003 Cohort P HG Event-Free Survival (%) Time from First Treatment or Re-induction (Weeks) Median follow-up was 6.0 months 8 patients were reinduced Consistent and high HG-EFS for both HG Ta an
Slide 15: Well Positioned in HR BCG-UR NMIBC with HG Ta/T1
Cretostimogene is Well Positioned in HR BCG-UR NMIBC with HG Ta/T1 with Potentially Best-in-Disease EFS Endpoint1 Papillary Disease (HG Ta/T1) Trial (Status) BOND-003 COHORT P (Ph3 Ongoing)1 SunRISe-12 QUILT 3.0323 NCT027738494,5 KEYNOTE-0576 Drug Cretostimogene TAR-200 N-803 + BCG Nadofaragene Pemb
Slide 16: PIVOT-006 Intermediate-Risk NMIBC Trial Design
RFS at 12-month and 24-month PFS Safety Additional Endpoints Intermediate-Risk (IR) NMIBC (Enrollment Completed) Cretostimogene vs Surveillance/TURBT Randomized (1:1), Two Arms, Open-Label (n=364) Primary Endpoint: RFS Rate Study Design / Regimen Arm A = Cretostimogene following TURBT Induction cour
Slide 17: Potential for First-in-Class Adjuvant Therapy in IR NMIBC
Cretostimogene* TAR-210 UGN-102 (approved) IR NMIBC LG Newly Diagnosed IR NMIBC LG Recurrent IR NMIBC HG Ta <3cm Adjuvant Excludes: HG Ta <3cm Excludes FGFR wildtype mutations Includes: All LG & HG <3cm Potential for first IR adjuvant therapy Excludes: HG Ta <3cm Excludes de novo LG Pre-TURBT which
Slide 18: CORE-008 Cohort CX Combination with Gemcitabine
Phase 2 Cretostimogene in Combination for High-Risk (HR) BCG-Exposed & BCG-Unresponsive NMIBC (Cohort CX) CORE-008 Cohort CX CR at any time CR at 12 months DoR PFS CFS Additional Endpoints HR BCG-Exposed & BCG Unresponsive NMIBC Cretostimogene + Gemcitabine 1:1 Randomized, Two Arm, Open-Label Primar
Slide 19: CORE-008 Cohorts A and B Monotherapy
Phase 2 Cretostimogene Monotherapy for High-Risk (HR) BCG-Naïve and BCG-Exposed NMIBC (Cohort A and B) CORE-008 Cohort A DoR (in CIS) EFS, LG-RFS, CFS Cohort B DoR (in CIS) EFS, LG-RFS, CFS Additional Endpoints HR BCG-Naïve & BCG-Exposed (Actively Enrolling) Cretostimogene Two Cohorts (A and B), Two
Slide 20: High Initial Response Rates from CORE-008 Cohort A
High Initial Response Rates from CORE-008 Cohort A CORE-008 Cohort A (n=49*) Overall Complete Response 83.7% (95% CI, 70.33% - 92.7%) CR (n=41) 25 Overall CR Rate (%) (n=49)1 50 75 100 0 CR Landmark Analysis CR Rate, % (95% CI) Original Administration2 (5-step) 79.2% (57.8, 92.9) 19 out of 24 patien
Slide 21: Advancing Cretostimogene to Optimized Administration
Advancing Cretostimogene to Optimized Administration Optimized Administration Cohort A data demonstrates efficacy and safety supporting optimized administration Meaningful benefit to patients and sites (esp. high-volume centers) with ~20-minute time savings Administered via soft catheter by medical
Slide 22: Key Clinical Metrics Driving HCP Treatment Decisions
Key Clinical Metrics Driving HCP Treatment Decisions in High-Risk BCG-unresponsive NMIBC* *Market Research across ~100 US HCPs (n=46 urologists, n=54 uro-oncologists), Survey was fielded Nov-Dec 2025 Chart represents percentages ranking as top 3 factors that drive treatment decisions
Slide 23: Capital-Efficient, High-Touch Launch Approach
CG is Building a Capital-Efficient, High-Touch Approach in Anticipation of a Successful Launch Across a Concentrated Prescriber Network Field Force Commercial Team: Key Account Managers Health System Directors Regional Business Directors National Account Leads Medical Science Liaisons Physicians Tre
Slide 24: The Path to 150K+ Addressable Patients
The Path to 150K+ Addressable Patients NMIBC = Non-muscle invasive bladder cancer; HR = high-risk; IR = Intermediate-risk TAM derived from NIH SEER, secondary claims data analytics, and management assumptions 150K+ Annualized WAC of approved therapies in HR NMIBC range from $200K to $690K 50K 50K 25
Slide 25: Catalyst Rich Calendar Through Potential First Approval and Launch
Catalyst Rich Calendar Through Potential First Approval and Launch Followed by Frontline Bladder Indication Expansion Anticipated Milestones* BCG-UR = BCG-unresponsive. HR = High-Risk Note: Timing and achievement of milestone events are based on Company estimates and subject to risks and uncertainti
Slide 26: Contact Us
www.CGOncology.com CONTACT US CG Oncology, Inc. 400 Spectrum Center Dr Suite #2040 Irvine, CA 92618 GENERAL INQUIRIES Information@cgoncology.com MEDIA MediaRelations@cgoncology.com
Slide 27: Executive Leadership Team
b b b Arthur Kuan Chairman & CEO Business Insider’s 30 People Under 40 Who Are Transforming Healthcare 2020 Forbes 30 Under 30 featured honoree in healthcare b Ambaw Bellete President & COO Vijay Kasturi, M.D. Chief Medical Officer 30+ Years in Biotech & Life Sciences with multiple BLA approvals & l
Slide 28: Our Vision and Mission
Our Vision We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. Our Mission We are focused on developing bladder-sparing therapeutics for patients afflicted with bladder cancer. Attacking Bladder Canc